Current stock page

Stock Analysis

IDEXX Laboratories, Inc. (IDXX) Stock Analysis

IDEXX Laboratories, Inc. (IDXX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.

IDXX Stock Analysis Summary

IDEXX Laboratories, Inc. (IDXX) currently has an AIQ Score of 44/100, indicating a neutral setup. Quality is the strongest factor at 88/100. Momentum is the weakest current factor at 9/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Sep 11, 2026 · Market-close data

IDXX at a Glance

Crawlable current metrics from the latest market-close stock snapshot.

MetricCurrent
Price$504.70
AIQ Score44/100
Overall ViewNeutral
Technical Analysis ConsensusStrong Sell
Market Cap$43B
P/E Ratio38.34
Forward P/E
EPS$4.23
Revenue TTM$1.22B
Dividend Yield0.00%
Beta1.54
Volume401.63K
52-week range$500.61-$769.98
RSI 1423.79
50-Day SMA$556.05
200-Day SMA$603.46
Analyst Price Target$656.67
Next EarningsNov 2, 2026
As of Sep 11, 2026 · Market close
Free research limit

Create a free account to keep researching stocks

You have viewed 2 stock pages in the last 24 hours. Create a free account to keep researching current evidence.

IDXX

Overview
IDEXX Laboratories, Inc.
Healthcare· Medical - Diagnostics & Research
AIQ Score
NeutralAIQ Edge 3/10
Low Priority
Relative Laggard
Score data as of Sep 11, 2026
Last price
$504.70
-$1.83 (-0.36%)
Latest market quote
Momentum9
Value26
Quality88
Risk Resilience50
Sentiment
View financial data

IDXX Stock Analysis Summary

IDEXX Laboratories, Inc. (IDXX) currently has an AIQ Score of 44/100, indicating a neutral setup. Quality is the strongest factor at 88/100. Momentum is the weakest current factor at 9/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.

Updated Sep 11, 2026 · Market-close data
AIQ Composite Posture: Mixed

In a neutral regime, IDXX has AIQ Score of 44/100 with Quality base of 88/100 and fading Momentum at 9/100. Wait for component alignment before adding exposure.

Signal Conflict Detected

Quality (88/100) leads while Momentum (9/100) lags. This cross-factor spread creates entry timing uncertainty.

Healthcare · -0.36% stock move · IDXX classified in Medical - Diagnostics & Research.

Current Evidence

NeutralIDXX is in a neutral AIQ regime; Quality is the strongest visible factor at 88/100.
Core coverage reflects visible evidence only

AlgovestIQ Evidence Summary

Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.

Is IDXX Bullish or Bearish Right Now?

IDXX currently has a neutral overall setup. Quality is the strongest factor at 88/100, while Momentum is weakest at 9/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.

Bull Case
  • - Quality is supportive at 88/100.
  • - Analyst target implies +30.11% upside from the latest quote.
Bear Case
  • - Value is the current constraint at 26/100.
  • - Momentum is weak at 9/100.
  • - Price is -16.37% below its 200-day SMA.
  • - Technical consensus has more sell votes than buy votes (36 vs 8).

Current Consensus

IDXX's Technical Analysis Consensus is currently Strong Sell, with 8 buy, 1 neutral, and 36 sell votes. IDXX's 14-day RSI is 23.79, which places the stock in an oversold momentum range. IDXX's beta is 1.54, indicating greater market sensitivity than the broad market.

Signal Confidence
High agreement

What Changed in IDXX?

Recent score-change history is not available in the current snapshot. These are the latest market-close scores instead.

AIQ Score
44/100
Momentum
9/100
Quality
88/100
Risk
50/100

What Would Change the IDXX Outlook?

The current neutral outlook could improve if AIQ moves above 70, momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 40, price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.

Bullish confirmation

AIQ > 70, RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.

Bearish deterioration

AIQ below 40, RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.

IDXX Decision Framework

Public evidence layers, setup checks, and risk context for IDEXX Laboratories, Inc..

IDEXX Laboratories, Inc. (IDXX) Stock Analysis

IDEXX Laboratories, Inc. has an AIQ Score of 44/100 in a Neutral regime. Quality is strongest at 88/100. Beta is 1.54, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.

Evidence LayerPublic Evidence
Regime ContextIDXX is in a Neutral AIQ regime with score 44/100.
Signal ConflictThe primary conflict is that quality leads at 88/100 while momentum lags at 9/100.
Factor EvidenceMomentum 9/100 · Value 26/100 · Quality 88/100 · Risk 50/100
PersistenceCurrent snapshot evidence is shown; historical persistence remains in AIQ Pro.

Current Setup Checklist

Factor strengthPass

Quality is the strongest factor at 88/100.

TimingFail

Momentum is 9/100 and RSI (14) is 23.8.

Regime fitWait

IDXX is in a Neutral regime at 44/100.

Risk controlWait

Risk factor is 50/100 with beta 1.54 and annual volatility 32.18%.

ConflictWait

Current conflict: quality leads at 88/100 while momentum lags at 9/100.

AIQ Score
44/100
Price
$504.70
Beta
1.54
RSI (14)
23.8

IDXX Research Cluster

Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.

IDXX Fundamentals

IDXX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.

Revenue
$1.22B
Net income
$338.41M
Free cash flow
$322.52M
View full IDXX fundamental analysis

IDXX Technical Analysis

IDXX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.

Technical Analysis Consensus
Strong Sell
RSI 14
23.79
Price vs SMA-50
-9.23%
View full IDXX technical analysis

IDXX Stock Catalysts

Track IDXX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.

Next earnings
Nov 2, 2026
Analyst target
$656.67
News items
3
View IDXX earnings and stock catalysts

IDXX Dividend Analysis

IDXX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.

Dividend yield
0.00%
Annual dividend
Payout ratio
View IDXX dividend history and analysis

IDXX Financial Data

IDXX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.

Quarter revenue
$1.22B
EPS
$4.23
Periods
8
View IDXX financials

IDXX Risk Analysis

IDXX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.

Beta
1.54
Risk score
50/100
1Y volatility
32.18%
View IDXX risk analysis

IDXX Stock News

IDXX stock news, market tone, recent headlines, and catalyst context.

News items
3
Updated
Sep 11, 2026
Sentiment
Read IDXX stock news

IDXX vs Medical Devices Peers

Current peer cohort: IDXX · INSP · ISRG · LMAT · MDT. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.

PeerAIQValueMomentumRiskSharpe1Y VolatilityCompare
IDXX
Current stock
44/10026/1009/10050/100-0.6932.18%Current
INSP
Inspire Medical
66/10049/10080/10056/1000.1871.15%IDXX vs INSP
ISRG
Intuitive Surgical
49/10026/10032/10064/100-0.4636.71%IDXX vs ISRG
LMAT
LeMaitre Vascular
50/10032/10039/10063/100-0.1744.78%IDXX vs LMAT
MDT
Medtronic
64/10058/10053/10073/100-0.1123.43%IDXX vs MDT
Pairwise Compare links: INSP · ISRG · LMAT · MDTIDXX vs INSPIDXX vs ISRGIDXX vs LMATIDXX vs MDTCompare cohort

Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Sep 11, 2026.

About the AIQ Score

Methodology for the current stock evidence.

As of Sep 11, 2026 · Market close

The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.

View AIQ methodology

Factor Diagnostics

A compact bridge from the AIQ score to the evidence tabs.

Calculator
Calculate a IDXX stock return scenario

Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.

Calculate stock return

AIQ Component Profile

Compare the five component scores on one consistent 0–100 scale.

Catalyst preview

Review earnings timing, revisions, news pressure, and prior event reactions in one place.

Open catalysts
Quarterly evidence

8 recent quarterly periods are available for review.

Checked Sep 12, 2026

AIQ Pro

Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.

Fundamentals Verdict

Current snapshot fields are separate from reported-quarter statement tables.

Current TTM P/E
38.28
As of Sep 11, 2026
Revenue growth
6.64%
Gross margin
62.45%
Current debt / equity
0.68
Latest quarterly evidence

Latest period Jun 30, 2026.

Review fundamentals
Quarter revenue
$1.22B
Quarter net income
$338.41M
Quarter free cash flow
$322.52M

Market Confirmation

Technicals are summarized first, with the indicator library behind it.

Trend
Bearish
Momentum
Bearish
RSI 14
23.79
MACD
-13.26

Risk Alignment

Higher resilience is stronger; exposure metrics stay separate.

Resilience
50/100
Beta
1.54
Annual volatility
32.18%
Max drawdown
-34.17%

IDXX Stock FAQ

What is IDXX stock price today?

IDEXX Laboratories, Inc.'s current stock price is $504.70. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.

Is IDXX bullish or bearish right now?

IDXX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.

What is IDXX's market cap?

IDXX's market cap is $43B based on the latest completed market-close snapshot from Sep 11, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.

What is IDXX's current P/E ratio?

IDXX's current P/E ratio is 38.34 based on the latest completed market-close snapshot from Sep 11, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.

What is IDXX's RSI?

IDXX's 14-day RSI is 23.79 based on the latest completed market-close snapshot from Sep 11, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.

Is IDXX above its 50-day and 200-day moving averages?

IDXX is -9.23% from its 50-day SMA and -16.37% from its 200-day SMA based on the latest completed market-close snapshot from Sep 11, 2026. Moving-average position should be read with momentum and broader AIQ evidence.

When is IDXX's next earnings date?

IDXX's next earnings date is currently listed as Nov 2, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.

Does IDXX pay a dividend?

IDXX's dividend yield is 0.00% based on the latest completed market-close snapshot from Sep 11, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.